Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Extended-duration dosing and distribution of dalbavancin into bone and articular tissue.

Dunne MW, Puttagunta S, Sprenger CR, Rubino C, Van Wart S, Baldassarre J.

Antimicrob Agents Chemother. 2015 Apr;59(4):1849-55. doi: 10.1128/AAC.04550-14. Epub 2015 Jan 5.

2.

Cardiac safety of rasagiline, a selective monoamine oxidase type B inhibitor for the treatment of Parkinson's disease: a thorough QT/QTc study.

Mendzelevski B, Sprenger CR, Spiegelstein O, Rabinovich-Guilatt L.

Int J Clin Pharmacol Ther. 2014 Mar;52(3):192-201. doi: 10.5414/CP201955.

PMID:
24447649
3.

Effects of injectable HPβCD-diclofenac on the human delayed rectifier potassium channel current in vitro and on proarrhythmic QTc in vivo.

Carr DB, McDonnell Moorehead T, Bouchard A, Sprenger CR, Hamilton DA, Lang E, Madden D, Lacouture PG, Wright C 4th.

Clin Ther. 2013 May;35(5):646-58. doi: 10.1016/j.clinthera.2013.03.014. Epub 2013 Apr 8.

4.

Absence of QTc prolongation in a thorough QT study with subcutaneous liraglutide, a once-daily human GLP-1 analog for treatment of type 2 diabetes.

Chatterjee DJ, Khutoryansky N, Zdravkovic M, Sprenger CR, Litwin JS.

J Clin Pharmacol. 2009 Nov;49(11):1353-62. doi: 10.1177/0091270009339189. Epub 2009 Sep 8.

PMID:
19737980

Supplemental Content

Loading ...
Support Center